Empfohlen
Empfohlen
Weitere ähnliche Inhalte
Andere mochten auch
Andere mochten auch (20)
Ähnlich wie In Sea2海洋多酚
Ähnlich wie In Sea2海洋多酚 (20)
Kürzlich hochgeladen
Kürzlich hochgeladen (6)
In Sea2海洋多酚
- 2. ˙ 飲食習慣、生活型態、活動力皆與肥胖息息相關。飲食種類 偏向 高油脂、高糖分攝取、低纖維飲食 ， 生活三餐不正常 ， 不 運動 ，慢慢的熱量不易被消耗代謝，最後導致脂肪的堆積，結 果胖子形成。 ˙ 根據統計資料顯示， 95% 肥胖是因為環境及生活習慣所引 起，導致體內囤積過多的脂肪，僅有 5% 與遺傳因素相關。 現代文明病
- 3. （ 1 ）腹部肥胖 （ 2 ）高血壓 （ 3 ） 高血糖 （ 4 ） HDL-C 過低 （ 5 ）高三酸甘油酯 代謝症候群定義 依據國民健康局 96 年 1 月修正我國代謝症候群臨床診斷準則公告， 即以下 5 項危險因子中，若包含 3 項或以上者即可判定。
- 6. 醣類的組成 麥芽糖 乳糖 蔗糖 由兩個單醣以共價鍵結合而成，常見的有：蔗糖、麥芽糖、乳糖。 雙醣類 果糖 半乳糖 葡萄糖 這是碳水化合物的最小構造單位，食品中最常見形式含 6 個碳原子，稱為「六碳醣」。天然食品中單獨存在的單醣之含量並不多，主要是作為雙醣、寡醣與多醣的構造單位，因此存在各種雙醣、寡醣與多醣的分子內。 單醣類 主要成分 說 明 類 別 肝醣 澱粉 由數百至數千個單醣分子連合而構成的大分子，主要存在植物性食品，飲食中常見的有澱粉、纖維素等。 多醣類 乳寡糖 果寡糖 水蘇糖 棉籽糖 由 3-10 個單醣結合而成，存在植物或微生物，雖然含量不高，但是種類很多，例如：豆類所含的水蘇糖與棉籽糖，果寡糖等。 寡醣類
- 9. α (1-4) bonds Target for α -amylase α (1-6) bond Starch 澱粉 醣類在體內分解的過程
- 10. Oligosaccharides Starch α -amylase 會切斷澱粉變成多種分子較小的寡醣類
- 12. Oligosaccharides Glucose α -glucosidase 由小腸的刷狀緣所分泌，主要是將寡醣與雙醣分解成單醣 ( 葡萄糖 ) ，以利進入腸道吸收利用。
- 13. 葡萄糖，提供能量來源
- 17. Before returning to baseline, a transient, barely noticeable postprandial hypoglycemic period can happen With high GI meals, the blood glucose curve shows a sharper rise, leading to an earlier peak in blood glucose In that case, postprandial hypoglycemia can be of greater magnitude and duration than in normal diet When low GI food is absorbed, glucose absorption occurs over a longer period of time and does not lead to postprandial hypoglycemia In normal conditions, blood glucose rises and returns to baseline after absorption of a standard meal 血糖與升糖指數 GI Time / hours Blood glucose 1 2 Hi GI Low GI Medium GI
- 24. 體外實驗： α -amylase inhibition assay
- 25. 體外實驗： α -glucosidase inhibition assay
- 26. 作用機轉 InSea 2 可降低餐後碳水化合物的吸收。 InSea2 可以抑制澱粉與澱粉酶結合的機會。
- 28. 90 % reduction Glycemia In vivo 飯後 30 分鐘血糖變化 InSea2 組可有效的降低 90% 血糖的上升。
- 29. 40 % reduction Insulinemia InSea2 組可降低 40%insulin 的分泌。 In vivo 飯後 30 分鐘 Insulin 分泌情形
- 30. Glucose (mmol/L) Time (min) Postprandial hypoglycemia in the placebo group p<0,05 InSea2 ™ 能將高 GI 食物轉換成低 GI 。 In vivo 血糖變化 Placebo InSea 2 ™
- 31. Insulin (pmol/L) Time (min) p=0,12 InSea2 ™ 能將高 GI 食物轉換成低 GI 。 In vivo Insulin 分泌情形 Placebo InSea 2 ™
- 37. 實驗結果 - 血糖影響
- 38. 實驗結果 - 器官影響
- 41. 市售產品
- 42. 競品 (phase 2) 比較總表 無 降低 22% 胰島素分泌 胰島素影響 有低血糖現象 無 造成飯後低血糖 ( 詳見 P44) 20000 AAIU/g 抑制葡萄糖苷活性 降低 66% 血糖吸收 降低 44% 血糖吸收 血糖影響 3000 AAIU/g 20000 AAIU/g 抑制澱粉酶活性 1.5g 抑制 264.13 Kcal/meal 0.5g 抑制 176 Kcal/meal 熱量吸收 ( 詳見 p46) 1. 抑制 α-amylase 1. 抑制 α-amylase, 2. 抑制 α-glucosidase 阻醣作用 Phaselarmin 海洋多酚 活性成分 白腎豆 兩種褐藻萃取物 來源 Phase2 InSea2
- 47. Phase2 相關文獻 : 減重效果不佳 Weight loss not significant from placebo Trend in reduction of serum triglycerides 體重無明顯改變 Study 1: Significant reduction in postprandial glycemia (at t=60 min) 降低 66% 葡萄糖的吸收 , 60 分鐘後會產生飯後低血糖的情形 Study 2: No significant change in AUC or glycemia values GI not significant from control with any encapsulated product (even with 3000 mg). GI not significant from control for lower powder doses (1500 and 2000 mg), but significant for 3000 mg 3000mgGI 值才有顯著差異 Weight loss significantly greater than placebo 體重無明顯改變 Weight loss not significant from placebo 體重無明顯改變 Results 8 weeks Single use 6 single use 12 weeks 4 weeks Duration Powder mixed with meal Capsule or powder mixed with meal Soft chewable Capsule Form 1500 mg BID Study 1: 1500 mg Study 2: 750 mg 1500, 2000 or 3000 mg 1000 mg TID 1000 mg bid Dose RDBPC RDB crossover OL Crossover RDBPC RDBPC Design 50 obese Study 1: 11 healthy Study 2: 7 healthy 13 healthy 60 overweight 25 healthy n Udani (3) Vinson et al. Udani (2) Rothacker Udani Study
Hinweis der Redaktion
- Here is first the data that we have obtained in vitro on human alpha amylase and alpha glucosidase enzymes. As you can see, the inhibition of both enzymes by InSea2 occurs in a dose-dependant manner. Doses of 20 to 50 mg/L bring us close to complete inhibition with both enzymes. CLICK The IC 50 for alpha-amylase is below 3 mg/L and below 10 mg/L for alpha-glucosidase. The recommended dose for our product being 500 mg, you can see here that we are recommending an amount between 25 and 50 times the requirements for an effective blockage of both enzymes. At 500 mg, a gastric volume of 50 L would be required to reach doses equivalent to our IC50 for alpha-glucosidase. Of course, the volume of our stomach is greatly lower than that. CLICK Here, you have a clear demonstration of the first key benefit of InSea2. It can inhibit two key enzymes involved in starch degradation and assimilation.
- Here you can see the blood glucose curve in its entirety, including the result after 30 minutes presented earlier. I am showing this for two purposes. First, the changes that we see in the blood glucose curves between placebo and InSea2 mimic what would be expected in shifting from a hi GI food to a low GI food. Glucose absorption occurs over a short period of time in the placebo curve whereas it spans as much as 3 hours in the InSea2 curve. CLICK Furthermore, we saw postprandial hypoglycaemia in the placebo curve, which also is a typical feature of hi GI foods. We see none of this in the InSea2 curve. CLICK In a nutshell, our data shows that InSea2 was able to change a high-GI food into a low-GI food, by inhibiting alpha-amylase and alpha-glucosidase. More importantly, these results were all obtained by using a dose which is similar to the recommended dose of 500mg. This result and the one shown on the preceding slide also support our third key feature for InSea2, stating that the product slows down insulin response and eliminates postprandial hypoglycaemia in vivo.
- Here you can see the blood glucose curve in its entirety, including the result after 30 minutes presented earlier. I am showing this for two purposes. First, the changes that we see in the blood glucose curves between placebo and InSea2 mimic what would be expected in shifting from a hi GI food to a low GI food. Glucose absorption occurs over a short period of time in the placebo curve whereas it spans as much as 3 hours in the InSea2 curve. CLICK Furthermore, we saw postprandial hypoglycaemia in the placebo curve, which also is a typical feature of hi GI foods. We see none of this in the InSea2 curve. CLICK In a nutshell, our data shows that InSea2 was able to change a high-GI food into a low-GI food, by inhibiting alpha-amylase and alpha-glucosidase. More importantly, these results were all obtained by using a dose which is similar to the recommended dose of 500mg. This result and the one shown on the preceding slide also support our third key feature for InSea2, stating that the product slows down insulin response and eliminates postprandial hypoglycaemia in vivo.